Disease burden of overactive bladder: Quality-of-life data assessed using ICI-recommended instruments

PharmacoEconomics

Volumn 25, Issue 2, 2007, Pages 129-142

  Basra, Ramandeep ^a   Kelleher, Con ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; DARIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE;

ABDOMINAL PAIN; BACKACHE; BLADDER RECONSTRUCTION; BLADDER TRAINING; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; HEADACHE; HEALTH CARE PLANNING; HEALTH STATUS; HEART DISEASE; HUMAN; INTERMETHOD COMPARISON; LIFESTYLE MODIFICATION; LOWER URINARY TRACT SYMPTOM; MICTURITION DISORDER; NEUROMODULATION; NOCTURIA; OVERACTIVE BLADDER; PATIENT ASSESSMENT; PATIENT SATISFACTION; POLLAKISURIA; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; XEROSTOMIA;

CLINICAL TRIALS; HUMANS; QUALITY OF LIFE; QUESTIONNAIRES; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 33846618172     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725020-00005     Document Type: Review

References (62)

1. Abrams P, Cardozo L, Khoury S, et al. Incontinence: volume 1. Basics and evaluation. Paris: Health Publications Ltd, 2005
2. Kelleher CJ, Cardozo L, Chapple CR, et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005; 95 (1): 81-5
3. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 May; 20 (6): 327-36
4. Milson I, Abrams P, Cardozo L, et al. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87 (9): 760-6
5. Sand PK, Hill RC, Ostergard DR. Incontinence history as a predictor of detrusor stability. Obstet Gynecol 1988; 71 (2): 257-60
6. Wyman JF, Choi SC, Harkins SW, et al. The urinary diary in evaluation of incontinent women: a test-retest analysis. Obstet Gynaecol 1988; 71: 812-7
7. Larrson G, Victor A. Micturition patterns in a healthy female population, studied with a frequency/volume chart. Scand J Urol Nephrol Suppl 1998; 114: 53-7
8. Barnick C. Frequency/volume charts. In: Cardozo L, editor. Urogynecology: the Kings approach. New York: Churchill Livingstone, 1997
9. Cardozo L, Staskin D. Textbook of female urology and urogynaecology. Oxford: Isis Medical Media, 2001
10. Lose G, Jorgensen L, Thunedborg P. 24-hour home pad weighing test versus 1-hour ward test in the assessment of mild stress incontinence. Acta Obstet Gynecol Scand 1989; 68: 211-5
11. Miller JM, Ashton-Miller JA, DeLancey JOL. The quantitative paper towel test for measuring stress related urine loss [abstract]. Proc Am Urogynecologic Soc, 18th Annual meeting. Tuscon: American Urogynecologic Society, 1997 Sep 25-28: 44
12. Cardozo L, Dixon A. Increased warning time with darifenacin: a new concept in the management of urinary urgency. J Urol 2005; 173: 1214-8
13. Chapple C, Artibani W, Cardozo L, et al. The role of urinary urgency and its measurement in the overactive bladder symp-tom syndrome: current concepts and future prospects. BJU Int 2005; 95: 325-40
14. Rodriguez LV, Blander DS, Dorey F, et al. Discrepancy in patient and physician perception of patient's quality of life related to urinary symptoms. Urology 2003; 62 (1): 49-53
15. Neumann PJ, Araki SS, Gutterman EM. The use of proxy respondents in studies of older adults: lessons, challenges, and opportunities. J Am Geriatr Soc 2000 Dec; 48 (12): 1646-54
16. Ware JE, Shebourne CD. The MOS 36-item- short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992 Jun; 30 (6): 473-83
17. Kelleher CJ, Cardozo LD, Khullar V, et al. A new questionnaire to assess the quality of life of urinary incontinent women. BJOG 1997; 104 (12): 1374-9
18. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OABq. Qual Life Res 2002; 11 (6): 563-74
19. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-172
20. Avery K, Donovan J, Peters TJ, et al. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 2004; 23 (4): 322-30
21. Coyne KS, Matza LS, Kopp Z, et al. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006 Jun; 49 (6): 1079-86
22. Camilleri-Brennan J, Ruta DA, Steele J. Patient generated index: new instrument for measuring quality of life in patients with rectal cancer. World J Surg 2002; 26 (11): 1354-9
23. The EuroQoL Group. EuroQoL: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16 (3): 199-208
24. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993 Apr 15; 118 (8): 622-9
25. Malone-Lee J, Shaffu B, Anand C, et al. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001 May; 165 (5): 1452-6
26. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50 (6A Suppl.): 90
27. Malone-Lee J, Eriksson M, Olofsson S, et al. The comparative tolerability and efficacy of tolterodine 2mg bid versus oxybutynin 2.5/5mg bid in the treatment of the overactive bladder. Conference of the International Continence Society; 1998 Apr 2-3; Cambridge, UK
28. Hunt SM, McKenna SP, McEwen J, et al. A quantitative approach to perceived health status: a validation study. J Epidemiol Community Health 1980 Dec; 34 (4): 281-6
29. Grimby A, Milstrom I, Molander U, et al. The influence of urinary incontinence on the quality of life of women of elderly women. Age Ageing 1993; 22 (2): 82-9
30. Bergner M, Bobbitt RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care 1981 Aug; 19 (8): 787-805
31. Hunskaar S, Vinsnes A. The quality of life in women with urinary incontinence as measured by the sickness impact profile. J Am Geriatr Soc 1991 Apr; 39 (4): 378-82
32. Oh SJ, Ku JH. Is a generic quality of life instrument helpful for evaluating women with urinary incontinence? Qual Life Res 2006 Apr; 15 (3): 493-501
33. Hannestad Y, Rortveit G, Sandvik H, et al. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT Study. J Clin Epidemiol 2000; 53 (11): 1150-7
34. Kelleher CJ, Kreder KJ, Pleil AM, et al. Long term health-related quality of life of patients receiving extended release tolterodine for overactive bladder. Am J Manag Care 2002 Dec; 8 (19 Suppl.): S616-30
35. Kobelt G, Kirchberger I, Malone-Lee J. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1999 Apr; 83 (6): 583-90
36. Chapple C, Kelleher C, Perrault L. Darifenacin an M3 selective receptor antagonist improves quality of life on patients with overactive bladder. Poster presented at World Health Organization's 3rd International Consultation on Incontinence; 2004 Jun 26-29; Monaco
37. Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase 3 studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005 May; 95 (7): 993-1001
38. Reese PR, Pleil AM, Okano GJ, et al. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. Qual Life Res 2003 Jun; 12 (4): 427-42
39. Coyne K, Matza L, MEDTAP. How responsive is the overactive bladder questionnaire (OAB-q) to changes in urgency episodes, micturitions and incontinence? [abstract; online]. Available from URL: www.icsoffice.org/ publications/2002 [Accessed 2006 Jan 8]
40. Shumaker SA, Wyman JF, Uebersax JS, et al. Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group. Qual Life Res 1994 Oct; 3 (5): 291-306
41. Flynn MK, Webster GD, Amundsen CL. The effect of botulinum-a toxin on patients with severe urge urinary incontinence. J Urol 2004 Dec; 172 (6 Pt 1): 2316-20
42. Wagner TH, Patrick DL, Bavendam TG, et al. Quality of life of persons with urinary incontinence; development of a new measure. Urology 1996; 47 (1): 67-71
43. Taylor SE, Brown JD. Positive illusions and well-being revisited: separating fact from fiction. Psychol Bull 1994 Jul; 116 (1): 21-7
44. Berghmans L, Nieman F, van Waalwijk van Doorn E, et al. Effects of physiotherapy, using the Dutch adapted I-QOL in women with urge incontinence [abstract]. Neurourol Urodyn 2001; 20: 509-10
45. Jackson S, Donovan J, Brookes S, et al. The Bristol female lower urinary tract symptoms questionnaire: development and psychometric testing. Br J Urol 1996 Jun; 77 (6): 805-12
46. Teleman P, Lidfeldt J, Nerbrand C, et al. Lower urinary tract symptoms in middle-aged women: prevalence and attitude towards mild urinary incontinence. A community-based population study. Acta Obstet Gynecol Scand 2005 Nov; 84 (11): 1108-12
47. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002; 168: 580-6
48. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464-70
49. Freeman R, Hill S, Millard R, et al. Tolterodine study group: reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol 2003; 102 (3): 605-11
50. Cardozo L, Coyne KS, Versi E. Validation of the urgency perception scale. BJU Int 2005 Mar; 95 (4): 591-6
51. Kelleher CJ, Pleil AM, Reese PR, et al. How much is enough and who says so? The case of the King's Health Questionnaire and overactive bladder. BJOG 2004 Jun; 111 (6): 605-12
52. Herbison P, Hay-Smith J, Ellis G, et al. Effectiveness of anti-cholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003 Apr 19; 326 (7394): 841-4
53. Lai HH, Boone TB, Appell RA. Selecting a medical therapy for overactive bladder. Rev Urol 2002; 4 Suppl. 4: S28-37
54. Jarernsiripornkul N, Krska J, Capps PAG, et al. Patient reporting of potential adverse drug reactions: a methodological study. BR J Clin Pharmacol 2002; 53 (3): 318-25
55. Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Uro 2005; 47: 376-84
56. Hassouna MM, Siegel SW, Nyeholt AA, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol 2000 Jun; 163 (6): 1849-54
57. Nabi G, Yong SM, Ong E, et al. Is orthoptic bladder replacement the new gold standard? Evidence from a systematic review. J Urol 2005 Jul; 174 (1): 21-8
58. Hautmann RE. Urinary diversion: ileal conduit to neobladder. J Urol 2003 Mar; 169 (3): 834-42
59. van Voskuilen AC, Oerlemans DJ, Weil EH, et al. Long-term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study. Eur Urol 2006 Feb; 49 (2): 366-72
60. Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006 July; 176 (1): 177-85
61. Rajkumar GN, Small DR, Mustafa AW, et al. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 2005 Oct; 96 (6): 848-52
62. Chapple C, Khullar V. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005; 48 (1): 5-26